We are live on ! Find out more
IGC icon

IGC Pharma

35 hedge funds and large institutions have $2.27M invested in IGC Pharma in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

144% more capital invested

Capital invested by funds: $929K → $2.27M (+$1.34M)

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

25% more funds holding

Funds holding: 2835 (+7)

2.1% more ownership

Funds ownership: 3.81%5.92% (+2.1%)

Holders
35
Holders Change
+7
Holders Change %
+25%
% of All Funds
0.46%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
8
Reduced
4
Closed
2
Calls
$8K
Puts
Net Calls
+$8K
Net Calls Change
+$8K

IGC Hedge Fund Activity: Q3 2025 in Review

35 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2025, worth a combined $2.27M — up 144% from $929K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IGC positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $443K. The largest seller was UBS Group, cutting an estimated $12.7K.

  • 35 institutional investors held IGC Pharma (IGC) as of Q3 2025, up from 28 in Q2 2025.
  • Funds reported $2.27M of IGC Pharma stock for Q3 2025, up 144% quarter-over-quarter.
  • 9 funds opened new IGC Pharma positions in Q3 2025 and 2 closed out, a net change of +7 holders.
  • The largest IGC Pharma buyer in Q3 2025 was Renaissance Technologies, an estimated $443K added.
  • The largest IGC Pharma seller in Q3 2025 was UBS Group, an estimated $12.7K sold.

Based on aggregated 13F filings for Q3 2025.